BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $8.89 Million

Equities research analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report sales of $8.89 million for the current quarter, Zacks reports. Four analysts have issued estimates for BioDelivery Sciences International’s earnings, with the highest sales estimate coming in at $9.52 million and the lowest estimate coming in at $8.37 million. BioDelivery Sciences International posted sales of $3.57 million in the same quarter last year, which suggests a positive year-over-year growth rate of 149%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that BioDelivery Sciences International will report full year sales of $8.89 million for the current financial year, with estimates ranging from $55.36 million to $64.10 million. For the next year, analysts anticipate that the business will post sales of $49.46 million per share, with estimates ranging from $44.33 million to $55.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a return on equity of 14.64% and a net margin of 3.34%. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.45 million. During the same quarter last year, the company posted ($0.31) EPS. The company’s quarterly revenue was up 74.0% compared to the same quarter last year.

A number of research analysts recently weighed in on the company. HC Wainwright set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, August 10th. Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.50 price objective on shares of BioDelivery Sciences International in a research report on Monday, August 14th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $4.21.

COPYRIGHT VIOLATION NOTICE: “BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $8.89 Million” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://transcriptdaily.com/2017/10/09/biodelivery-sciences-international-inc-bdsi-expected-to-post-quarterly-sales-of-8-89-million.html.

Shares of BioDelivery Sciences International (BDSI) opened at 3.00 on Monday. The company’s 50-day moving average price is $2.98 and its 200 day moving average price is $2.55. BioDelivery Sciences International has a one year low of $1.50 and a one year high of $3.60. The company has a market cap of $166.43 million, a P/E ratio of 107.14 and a beta of 0.95.

In related news, CEO Mark A. Sirgo sold 65,405 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark A. Sirgo sold 201,373 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $2.84, for a total value of $571,899.32. Following the transaction, the insider now directly owns 1,509,262 shares of the company’s stock, valued at approximately $4,286,304.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 402,127 shares of company stock valued at $1,142,798. 9.00% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Valley National Advisers Inc. increased its position in BioDelivery Sciences International by 59.0% during the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 14,000 shares in the last quarter. Stonepine Capital Management LLC increased its holdings in shares of BioDelivery Sciences International by 22.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after purchasing an additional 632,853 shares in the last quarter. KCG Holdings Inc. increased its holdings in shares of BioDelivery Sciences International by 469.9% in the 1st quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock worth $210,000 after purchasing an additional 91,297 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its holdings in shares of BioDelivery Sciences International by 5.9% in the 1st quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after purchasing an additional 56,550 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in shares of BioDelivery Sciences International by 10.1% in the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after purchasing an additional 44,700 shares in the last quarter. 41.43% of the stock is owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply